MediGene AG

euro adhoc: MediGene AG
Restructuring & Recapitalisations / MediGene Successfully Closes Capital Increase by 16.7 Million EUR As Announced (E)

---------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc.   The issuer is responsible for the content of this announcement. ---------------------------------------------------------------------

Martinsried - San Diego, March 24, 2004. After successful closure of the first step of the three-step capital increase measures announced on March 4, 2004, the German-American biotech company MediGene AG (Frankfurt, Prime Standard: MDG) has also successfully placed the second and the third step. The approximately 1.1 million new shares from the second capital increase, offered to the company's current shareholders at a subscription price of 6.80 EUR each, as well as the total of 1.5 million convertible bonds also offered to the shareholders at a price of 1.00 EUR each, have been fully placed with shareholders as well as institutional investors. Proceeds from the issue of new shares and convertible bonds, including the preceding first step of the capital increase, amount to 16.7 million EUR, thus raising the company's current cash available to almost 40 million EUR.

end of announcement            euro adhoc 24.03.2004
---------------------------------------------------------------------

Further inquiry note: Julia Hofmann Tel.: +49 (0)89 8565 3324 E-mail: j.kern@medigene.com

Branche: Biotechnology
ISIN:      DE0005020903
WKN:        502090
Index:    CDAX, Prime All Share, Prime Standard, Technologie All Share
Börsen:  Frankfurter Wertpapierbörse / regulated dealing
              Niedersächsische Börse zu Hannover / free trade
              Berliner Wertpapierbörse / free trade
              Bayerische Börse / free trade
              Hamburger Wertpapierbörse / free trade
              Bremer Wertpapierbörse (BWB) / free trade
              Börse Düsseldorf / free trade
              Baden-Württembergische Wertpapierbörse / free trade



Weitere Meldungen: MediGene AG

Das könnte Sie auch interessieren: